Active-site-inhibited plasmin was prepared by inhibition with D-valyl-L-phenylalanyl-L-lysylchloromethane or by bovine pancreatic trypsin inhibitor (Kunitz inhibitor). Active-site-inhibited Glu-plasmin binds far more strongly to fibrin than Glu-plasminogen [native human plasminogen with N-terminal glutamic acid (residues 1-790)]. This binding is decreased by a2-plasmin inhibitor and tranexamic acid, and is, in the latter case, related to saturation of a strong lysine-binding site. In contrast, a2-plasmin inhibitor and tranexamic acid have only weak effects on the binding of Glu-plasminogen to fibrin. This demonstrates that its strong lysine-binding site is of minor importance to its binding to fibrin. Active-site-inhibited Lys-plasmin and Lys-plasminogen (Glu-plasminogen lacking the N-terminal residues Glul-Lys76, Glul-Arg67 or Glul-Lys77) display binding to fibrin similar to that of active-sitg inhibited Glu-plasmin. In addition, a2-plasmin inhibitor or traneyamic acid similarly decrease their binding to fibrin. Glu-plasminogen and active-site-inhibited Glu-plasmin have the same gross conformation, and conversion into their respective Lys-forms produces a similar marked change in conformation [Violand, Sodetz & Castellino (1975) Arch. Biochem. Biophys. 170, 300-3051. Our results indicate that this change is not essential to the degree of binding to fibrin or to the effect of a2-plasmin inhibitor and tranexamic acid on this binding. The conversion of miniplasminogen (Glu-plasminogen lacking the N-terminal residues Glul-Val441) into active-site-inhibited miniplasmin makes no difference to the degree of binding to fibrin, which is similarly decreased by the addition of tranexamic acid and unaffected by a2-plasmin inhibitor. Active-site-inhibited Glu-plasmin, Lys-plasmin and miniplasmin have lower fibrin-binding values in a plasma system than in g purified system. Results with miniplasmin(ogen) indicate that plasma proteins other than a2-plasmin inhibitor and histidine-rich glycoprotein decrease thp binding of plasmin(ogen) to fibrin.
the Arg560-Val561 bond (Robbins et al., 1967; Wiman, 1977; Sottrup-Jensen et al., 1978) . This results in the formation of plasmin, composed of a heavy and a light chain connected by two disulphide bridges (Sottrup-Jensen et al., 1978) . Reactions b and d can be catalysed by plasmin and involve the cleavage of the Arg67-Met68, Lys76-Lys77 or Lys77-VaP78 bond, associated with the release of the N-terminal residues (Claeys et al., 1973; Wiman & Wallen, 1975; Violand & Castellino, 1976) . Reaction a is regarded as the initial, obligatory event. The rates of the reactions a-d depend on a complex interplay between activator, Glu-plasminogen and its derivatives, fibrin and a2-plasmin inhibitor (af antiplasmin). Reaction b markedly increases the binding of plasminogen to fibrin (Thorsen, 1975) and a2-plasmin inhibitor (Wiman et al., 1979) . Binding sites on plasmin(ogen) for fibrin, a2-plasmin inhibitor and L-lysine analogues are functionally interdependent (Thorsen, 1975; Wiman & Wallen, 1977; Aoki et al., 1978; Christensen et al., 1979; Wiman et al., 1979; Lerch et al., 1980; Thorsen et al., 198 la) .
The present study compares the change in secondary-site fibrin binding caused by reaction a with those caused by reactions b-d. The changes in fibrin binding are studied in the presence of a2-plasmin inhibitor, tranexamic acid (an L-lysine analogue) and in a plasma environment. The results are related to those obtained when miniplasminogen (neoplasminogen-Val442, K5 light chain), is converted into miniplasmin. Miniplasmin(ogen) lacks important binding sites for a2-plasmin inhibitor and L-lysine analogues, but has partially retained binding sites for fibrin Christensen et al., 1979; Thorsen et al., 1981b Tranexamic acid and D-Val-Leu-Lys-pNA (S-225 1) were from Kabi Ltd., Stockholm, Sweden. D-ValPhe-Lys-CH2Cl was used directly as a freeze-dried powder or as a stock solution (1 mmol/litre) in HCI (1 mmol/litre).
Proteins. Aprotinin (Trasylol) and human urokinase have been described (Thorsen & Miillertz, 1974) . This also applies to Glu-plasminogen, Lysplasminogen, miniplasminogen and a2-plasmin inhibitor (Thorsen et al., 198 lb (Kabi Ltd.) was purified by removing plasminogen with lysineSepharose 4B (Pharmacia, Uppsala, Sweden) (Noren et al., 1975) and by removing Factor XIII with organomercurial-agarose (Affi-gel 501; BioRad Laboratories, Richmond, CA, U.S.A.) (McDonagh et al., 1976) . The efficacy of Factor XIII removal was verified by SDS/polyacrylamidegel electrophoresis, which showed no y-chain dimerization of fibrin prepared in the presence of CaCl2 and incubated for 2h at 37°C. The coagulability of the purified preparation [mean + S.E.M. (n)] expressed as the ratio [clottable fibrinogen]/[fibrinogen] was 1.0 + 0.011 (10).
Human plasma. This was obtained from the blood of four normal subjects, freshly drawn with their informed consent, stabilized by 0.1 vol. of trisodium citrate (0.11 mol/litre). Factor XIII was removed by immunoprecipitation at 370C for 30min and overnight at 40C, by using 1 ml of specific rabbit antiserum against Factor XIII (subunit A) in 48ml of plasma. Clots, prepared in the presence of CaCl2 and incubated at 370C for 2h, could be dissolved within 3min in acetic acid (0.96 mol/litre)/urea (6.25 mol/litre).
Antibodies. Specific rabbit antiserum against human Factor XIII (subunit A) was from Behringwerke, Marburg/Lahn, Germany. Specific rabbit immunoglobulins against human urokinase have been described (Clemmensen & Christensen, 1976) .
Urokinase-Sepharose. This was prepared by coupling urokinase [4 x 104 Ploug units/g of dried CNBr-activated Sepharose 4B (Pharmacia)] according to the manufacturer's instructions.
Methods
Determination of protein concentrations. The concentrations of fibrinogen, clottable fibrinogen, plasmin(ogen) forms and a2-plasmin inhibitor were determined as described previously (Thorsen et al., 1981 b) . The concentration (absorbance) of plasmin in complex with aprotinin was corrected by using an Al%m280 value of 8.3 and mol.wt. 6513 (Kassell, 1970 Thorsen et al. (198 lb) . Preparation of aprotinin-inhibited '251-labelled plasmin. This was prepared essentially as described by and Summaria et al. (1975) . Tris buffer (I 0.15, 1 ml) containing plasminogen (40-60,umol Polyacrylamide-gel electrophoresis. SDS/polyacrylamide-gel electrophoresis was performed as described by Weber & Osborn (1975) , in the presence or absence of urea (6 mol/litre) (Violand & Castellino, 1976) . Polyacrylamide-gel electro- phoresis in acetic acid/urea at pH 3.2 was performed as previously described (Panyim & Chalkley, 1969; Walther et al., 1975 litre). This was followed by incubation for 1h at 560C. Acetic acid/urea/polyacrylamide-gel electrophoresis was especially suited to discriminate between Glu-plasminogen and its derivatives (Fig. 1) . Electrophoresis of unreduced samples clearly separates Glu-plasminogen from Lys-plasminogen (Walther et al., 1975) . Glu-and Lys-plasmin migrate as their respective proenzymes. Electrophoresis of reduced samples separates Glu-plasminogen, Lysplasminogen, Glu-plasmin heavy chain, Lys-plasmin heavy chain and plasmin light chain (Fig. 1) .
Autoradiography of polyacrylamide gels. Gels were shrunk in methanol/glycerol (1: 1, by vol.) for 24 h. This was followed by drying. Curix RPL X-Ray Film (Agfa-Gevaert) was used for exposure.
Quantification of '25I-labelled plasminogen derivatives by polyacrylamide-gel electrophoresis. The bands of labelled plasminogen material were excised from the rest of the gel track and their radioactivity quantified in a gamma well counter. Acetic acid/urea/polyacrylamide-gel electrophoresis of reduced samples yielded bands with the following radioactivities: a (Glu-plasminogen); b (Lys-plasminogen); c (miniplasminogen); d (Gluplasmin heavy chain); e (Lys-plasmin heavy chain); f (KS); and g (plasmin light chain). The sum of the radioactivities of the bands was t. The radioactive fraction (=the molar fraction of labelled substance) was calculated as (a/t) (Glu-plasminogen), (b/t) (Lys-plasminogen), (c/t) (miniplasminogen), { [d+ (d.g )/(d+ e)I/t} (Glu-plasmin), {[e+ (e-g)/(d+ e)I/ t} (Lys-plasmin) and [(f +g)/t] (miniplasmin). The conversion of 125I-labelled Glu-plasmin into Lysplasmin did not change the radioactivity of the heavy chain (S. Miillertz, unpublished work). Acetic acid/urea/polyacrylamide-gel electrophoresis of unreduced samples yielded bands with the following radioactivities: h (Glu-plasminogen + Glu-plasmin) and i (Lys-plasminogen + Lys-plasmin). The radioactive fraction (=the molar fraction of plasminogen + plasmin) was calculated as [h/(h + i)] (Gluforms) and [i/(h + i)] (Lys-forms). SDS/polyacrylamide-gel electrophoresis of reduced samples allowed quantification of radioactivities of plasminogen, plasmin heavy-chain, K5 and plasmin lightchain bands. No attempt was made here to distinguish Glu-from Lys-forms. With all forms of electrophoresis, t was greater than 0.92 of the total radioactivity in the gel track. The total radioactivity in the gel track, given as a fraction of the radioactivity of the sample applied to the gel, was more than 0.85. . Acetic acid/urealpolyacrylamide-gel electrophoresis of Glu-and Lys-plasminogen and their respective plasmin forms Glu-plasminogen: non-reduced (a) and reduced sample (e); Lys-plasminogen: non-reduced (b) and reduced sample (f); Glu-plasmin (prepared from aprotinin-inhibited Glu-plasmin by gel filtration at pH3): non-reduced (c) and reduced sample (g); Lys-plasmin (prepared from aprotinin-inhibited Lys-plasmin by gel filtration at pH 3): non-reduced (d) and reduced sample (h). The weak bands with greatest mobility in (g) and (h) are the plasmin light chains. The double-banded appearance of the non-reduced samples is presumably due to carbohydrate heterogeneity of the plasmin(ogen) molecules (Walther et al., 1975) .
Fibrin binding oflabelledplasmin(ogen). This was determined as previously reported (Thorsen et al., 1981b) . Clots (vol. 500Sl) [FB(Glu)] were therefore determined as (F-x)/ (T.y). The ratio (radioactivity of Glu-plasminogen + Glu-plasmin)/(total radioactivity of plasminogen material), was determined for the fibrin-bound plasminogen material (=x) and for the plasminogen material added to the clotting mixture (=y). This was done by acetic acid/urea/polyacrylamide-gel electrophoresis of unreduced samples. Attempts at determining fibrin binding of Glu-plasmin alone, by using acetic acid/urea/polyacrylamide-gel electrophoresis under reducing conditions, were unsuccessful, since fibrin interfered with the electrophoretic separation.
Results

Preparation conditions and characterization of active-site-inhibited Glu-and Lys-plasmin
The identities of the aprotinin and D-Val-PheLys-CH2Cl-inhibited plasmin preparations were verified by acetic acid/urea/-and SDS/-polyacrylamide-gel electrophoresis (inhibited Glu-plasmin and miniplasmin are shown in Fig. 2 ). In addition, the identities of the aprotinin-inhibited plasmin preparations were verified by N-terminal amino-acidsequence analysis (performed by L. Sottrup-Jensen) after separating plasmin from aprotinin by gel filtration on Sephadex G-75 at pH 3 (Suenson et al., 1980) . The Glu-plasmin preparation showed the N-terminal sequences Glu-Pro (heavy chain) and Val-Val (light chain), and Lys-plasmin showed the N-terminal sequences Lys-Val (heavy chain) and Val-Val (light chain). Quantification of the molar fractions of labelled plasminogen derivatives by SDS/-or acetic acid/urea/-polyacrylamide-gel electrophoresis of reduced samples showed preparations of aprotinin-inhibited 125I-labelled Glu- (Fig. 3) .] Owing to these circumstances, fibrin binding of active-site-inhibited Glu-plasmin was also determined as FB(Glu). This value was an estimate of the lower limit of the fibrin binding of active-site-inhibited Glu-plasmin. The upper limit was FB(total) as there was no evidence of selective adsorption of Glu-plasmin to fibrin. This was documented by the fact that radiolabelled material bound to the separated fibrin had a ratio [Gluplasmin(+Glu-plasminogen)]/[total plasmin(+total plasminogen)] which did not exceed that in the supernatant after removal of fibrin. Fibrin-binding of labelled plasminogen derivatives in the simple purified system Table 1 shows that active-site-inhibited Glu-or Lys-plasmin binds much more strongly to fibrin than does Glu-plasminogen and that they bind to the same extent as, or more strongly than,. Lysplasminogen. FB(total) was the same for aprotinin-inhibited Glu-and Lys-plasmin, indicating that (6) they had the same affinity for fibrin. The fibrin binding of the aprotinin-inhibited plasmin forms was higher than that of the D-Val-Phe-Lys-CH2Cl-inhibited plasmin forms (P<0.01). Conversion of miniplasminogen into D-Val-Phe-Lys-CH2Cl-inhibited miniplasmin made no difference to the extent to which it bound fibrin.
Aprotinin-inhibited Glu-or Lys-plasmin contained free aprotinin. The molar ratio (free aprotinin)/(aprotinin-plasmin complex) was 0.7. No attempt was made to remove this aprotinin, on account of the instability of the Glu-plasmin preparation, and this excess of aprotinin was shown not to influence the fibrin binding of Lys-plasminogen or D-Val-Phe-Lys-CH2Cl-inhibited Glu-plasmin.
The urokinase used in the preparation of DVal-Phe-Lys-CH2Cl-inhibited plasmin forms was removed by immunoprecipitation in order to avoid plasmin formation in systems containing unlabelled plasminogen. This did not influence the results, since fibrin binding was found to be the same before and after immunoprecipitation in the simple purified system. A280 measurements showed fibrinogen added to the clotting mixtures to be totally recovered as fibrin.
This was the case in the presence of each of the examined ligands. However, SDS/polyacrylamidegel electrophoresis of reduced samples showed some fibrin a-chain degradation in clots containing Lysplasminogen, miniplasminogen or D-Val-Phe-Lys-CH2CI-inhibited Glu-plasmin. The a-chain degradation was presumably caused by trace amounts of free plasmin in the ligand preparations. Addition of aprotinin (in amounts that did not exceed that of free amounts of it in aprotinin-inhibited plasmin) inhibited this degradation and did not alter fibrin binding. Glu-plasminogen and aprotinin-inhibited Glu-plasmin did not produce a-chain degradation. Fibrin-binding of labelled plasminogen derivatives in the presence of tranexamic acid or a2-plasmin inhibitor and in plasma clots Figs. 4 and 5 show that micromolar concentrations of tranexamic acid decreased the fibrin binding of Lys-plasminogen and inhibited Glu-and Lys-plasmin, but had no effect on Glu-plasminogen. The decrease in fibrin binding of Glu-plasminogen was insignificant (P <0.20) at all concentrations of tranexamic acid (10-330,umol/litre) in Fig. 4 . In Fig.   5 the decrease was significant (P <0.001) at 1 and lOmmol/litre. It is unlikely that the weak effect of tranexamic acid on fibrin binding was related to non-specific inclusion of the Glu-plasminogen-tranexamic acid complex in the fibrin network. This is substantiated by the fact that the fibrin binding of a variant of K 1 + 2 + 3 is the same as that of Glu-plasminogen and can be decreased from 0. (Thorsen et al., 1981b) . Tranexamic acid decreased the fibrin binding of D-Val-Phe-Lys-CH2Cl-inhibited miniplasmin to the same extent as previously reported for miniplasminogen (Thorsen et al., 1981b) . The concentration of the tranexamic acid that decreased fibrin binding of ligand by 50% was 1 lO,umol/litre for inhibited miniplasmin and 80,umol/litre for miniplasminogen (fibrinogen, 9.2,umol/litre; ligand, 1.2,umol/litre).
a2-Plasmin inhibitor decreased the fibrin binding of Lys-plasminogen, and D-Val-Phe-Lys-CH2Cl-inhibited Glu-and Lys-plasmin (Fig. 6 ), but its effect on labelled Glu-plasminogen was weak (at concentrations up to 10.9,umol/litre). It had no effect whatever on labelled miniplasminogen and D-ValPhe-Lys-CH2Cl-inhibited miniplasmin (results not shown). Indirect binding of plasminogen derivatives to fibrin through a2-plasmin inhibitor was avoided by using a Factor XIII-free assay system .
The fibrin binding of Lys-plasminogen, D-ValPhe-Lys-CH2Cl-inhibited Glu-plasmin, Lys-plasmin and miniplasmin was 1.8-2.8 times higher in fibrin clots than in plasma clots ( Table 2) Each point represents the mean of at least two determinations. Table 2 . Fibrin binding of 125I-labelled plasminogen derivatives in clotted plasma (A) clotted fibrinogen with Gluplasminogen and a2-plasmin inhibitor (B), and in clottedfibrinogen alone (C) The clotting mixtures all contained fibrinogen (5.04umol/litre), ligand (0.2,imol/litre) and CaCl2 (8mmol/litre). A and B also contained Glu-plasminogen (1.7 4amol/litre) and a2-antiplasmin (0.9,umol/litre). In A, 0.63 of the volume of the reaction mixtures was plasma. All values are given as FB(total), save those in square brackets, which are lower limits given as FB(Glu).
Fraction of radioactivity bound to fibrin same amounts of Glu-plasminogen and a2-plasmin inhibitor in the fibrin clots as were present in the plasma clots did not decrease the fibrin binding to the values found for plasma clots. These values were the same for Lys-plasminogen and active-siteinhibited Glu-and Lys-plasmin. The experiments were performed in the presence of CaCl2 (8 mmol/ litre), which did not alter the binding of plasminogen derivatives to fibrin (compare with Table 1 ).
Discussion
Conversion of Glu-plasminogen to active-siteinhibited Glu-or Lys-plasmin or to Lys-plasminogen results in a marked increase in fibrin binding (Table 1) . This corresponds to a 5-50-fold decrease in the apparent dissociation constant (Table 3) . Gluand Lys-plasmin(ogen) contain a number of sites, denoted 'lysine-binding sites', on the K1-4 parts of the molecules, that bind lysine analogues (Markus et al., 1978 (Markus et al., , 1979 (Markus et al., , 1981 . One of these sites on K1-3 has a particularly strong affinity. This site has been ascribed major importance in the binding of plasmin-(ogen) to fibrin and a2-plasmin inhibitor (Wiman & Wallin, 1977; Wiman et al., 1979) . However, the observation that tranexamic acid at concentrations below 330,umol/litre has no effect on the fibrin binding of Glu-plasminogen (Fig. 4) indicates that the strong lysine-binding site is not of major importance for the binding of Glu-plasminogen to fibrin. Micromolar concentrations of tranexamic acid radically decrease the fibrin binding of inhibited Glu-and Lys-plasmin and Lys-plasminogen (Figs. 4 and 5) . The calculated dissociation constants in Table 3 indicate that this is related to saturation of a strong lysine-binding site. The potent effect of tranexamic acid after formation of Glu-or Lys-plasmin or Lys-plasminogen may be explained as follows. On conversion of Glu-plasminogen, the strong lysine-binding site of the proenzyme adopts a favourable conformation so as also to bind fibrin. Alternatively, a hidden strong lysine-binding site is exposed that binds fibrin. In both cases tranexamic acid decreases fibrin binding by a competitive effect. There is, however, also the possibility that tranexamic acid may act as an allosteric effector, making a separate fibrin-binding site in the Glu-plasminogen derivative inaccessible to fibrin.
The weak effect of a2-plasmin inhibitor on the fibrin binding of Glu-plasminogen (Fig. 6 ) is compatible with the relatively low affinity between Glu-plasminogen and the inhibitor that was reported by Wiman et al. (1979) . The effect of micromolar concentrations of a2-plasmin inhibitor on the fibrin binding of D-Val-Phe-Lys-CH2Cl-inhibited Glu-or Lys-plasmin or on Lys-plasminogen (Fig. 6, Table 3 ) indicates that secondary-site a2-plasmin inhibitor affinity increases when Glu-plasminogen is converted into each of these derivatives.
Sedimentation-velocity experiments have shown Glu-plasminogen and aprotinin-inhibited Gluplasmin to have the same gross conformation. Conversion of Glu-plasminogen and inhibited Gluplasmin to their respective Lys-forms produce a similar marked change in conformation (Violand et al., 1975) . This change resembles that seen on complex-formation with L-lysine analogues (Violand et al., 1975) , and seems mainly to involve the K1-5 part of the plasminogen molecule (Gonzales-Gronow et al., 1977) . Our results indicate that this change in conformation is not essential to a high degree of fibrin binding or to the effect of a2-antiplasmin or tranexamic acid on this binding.
Aprotinin-inhibited Glu-or Lys-plasmin display higher fibrin binding than do the D-Val-Phe-LysCH2Cl-inhibited Glu-or Lys-forms. This difference could be due to side reactions of the chloromethane inhibitor (Shaw, 1975) causing modification of ligand residues involved in secondary-site fibrin binding. Cederholm-Williams & Swain (1979) , found p-nitrophenyl p'-guanidinobenzoate-inhibited Lysplasmin to bind strongly to fibrin. However, their plasmin may have been structurally altered, since it had been exposed to pH 2.5 during preparation. Acid treatment changes the physico-chemical and functional properties of Glu-plasminogen (Alkjaersig, 1964; Thorsen, 1977; Claeys & Collen, 1978) and markedly increases its fibrin binding (S. Thorsen, unpublished work) . Their clotting mixtures contained nanomolar concentrations of fibrinogen and ligand, and fibrin was enmeshed in crushed glass. In our hands these conditions introduce a significant error due to the adsorbtion of proteins to glass. This alone may explain why their dissociation constants for 'Lys'-plasmin(ogen) and fibrin are approx. 100 times lower than those in Table 3 .
The previously reported results on the fibrin binding of miniplasminogen (Thorsen et al., 1981b) are extended with the observation that conversion of miniplasminogen into D-Val-Phe-Lys-CH2Cl-inhibited miniplasmin makes no difference to the degree of fibrin binding (Table 1) or to the effect of a2-antiplasmin or tranexamic acid on this binding. For further discussion on this subject, see Thorsen et al. (1981b) . Tables 1 and 3 (columns headed B) show that the ligands associate more strongly to fibrin in the reaction mixtures containing low concentrations of fibrinogen and ligand. Separate experiments have shown this to be exclusively correlated with the fibrinogen concentration (Thorsen, 1975; S. Thorsen, unpublished work) . The kinetics of the fibrin binding of ligands ma'y therefore be more complex than assumed in Table 3 and may involve a heterogeneous population of fibrin monomers at different stages of polymerization.
Active-site-inhibited Glu-plasmin, Lys-plasmin and miniplasmin have low fibrin-binding values in plasma systems as compared with purified systems (Table 2) . Similar results have previously been reported for their proenzymes (Rakoczi et al., 1978; Lijnen et al., 1980; Thorsen et al., 1981b) . The low fibrin binding in the plasma system of Glu-plasmin-(ogen) and Lys-plasmin(ogen) can to a major extent be explained by a combined effect of a2-plasmin inhibitor and histidine-rich glycoprotein . However, the low fibrin binding in a plasma system of miniplasminogen and inhibited miniplasmin cannot be explained by a combined effect of a2-plasmin inhibitor and the histidine-rich glycoprotein, since miniplasmin(ogen) lacks important binding sites for these two pr6teins (Wiman et al., , 1979 Christensen et a4., 1979; Lijnen et al., 1980 [191 In conclusion, the results of the present study and that of Thorsen et al. (1981b) indicate that binding sites for fibrin, a2-antiplasmin and L-lysine analogues are interdependent, but may well not be identical.
